Is Tumor-Free Distance an Independent Prognostic Factor for Early-Stage Endometrioid Endometrial Cancer?

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Risk group</td><td class="align_center"><i>n</i> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Intermediate</td><td class="align_center">61 (45.8)</td></tr><tr><td class="align_left">High-intermediate</td><td class="align_center">42 (31.5%)</td></tr><tr><td class="align_left">High</td><td class="align_center">30 (22.5%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>ESMO: European Society for Medical Oncology; ESGO: European Society of Gynaecological Oncology; ESTRO: European Society for Radiotherapy and Oncology.<br/></div></td></tr></table>

<div>Risk groups of study populations according to the ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer.</div>

Journal of Oncology

tab1

Table 1

Table 1: Is Tumor-Free Distance an Independent Prognostic Factor for Early-Stage Endometrioid Endometrial Cancer? 